Technology
Taking targeted
cancer treatment
to the next level.
BioSyngen is utilizing our proprietary EBV platform to develop next-generation CAR-T and TCR-T therapies to target EBV related cancers.
In activating a strong immune response, our therapies not only destroy cancer cells but also critically reduce off-target or on target off tumor toxicities to preserve healthy cells,—ensuring enhanced safety and clinical efficacy in tandem.
Taking aim at
EBV antigens.
Epstein-Barr virus (EBV) related cancers are prevalent in Asia, yet most current therapies do not target such viral antigens. We are one of the few biotechs filling this gap in tumor immunotherapy.
Breaking barriers in
treating solid tumors.
Our therapies can effectively attack difficult-to-treat solid tumors by better recognizing tumor specific antigens found on the cancer cells and overcoming immunosuppressive TME
Diverse patients,
adaptive solutions.
Our EBV TCR library is the largest in the world and covers Caucasian and Asian populations, giving us greater flexibility in designing personalized T cell therapies.
Pipeline
Translating treatments from bench to bedside.
Multiple clinical trials are underway to advance immunotherapy solutions, enabled by BioSyngen’s extensive clinical network and large-scale GMP manufacturing capabilities.
As we strive to create a brighter future for cancer patients and their families, Biosyngen is combining innovative technologieswith medical expertise en route to becoming a visionary biotechunicorn in Singapore and the region.
News
Mar 29, 2023
The city of Guangzhou welcomes Singapore Prime Minister Lee Hsien Loong, the first stop of his week-long visit to China. Accompanying PM Lee in this trip are Foreign Minister Vivian Balakrishnan, Trade and Industry Minister Gan Kim Yong, He...
Apr 19, 2023
April 15, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) announced that the Company received IND approval for its second product in the pipeline, a T-cell redirection therapy for the treatment of EBV-positive lymphoma. A week prior to...
Apr 11, 2023
April 7th, 2023, Biosyngen Pte Ltd (hereinafter as “Biosyngen”) was granted IND approval by China NMPA for the company’s first-in-class T-cell redirection therapy, it is an autologous T cell therapy for EBV-positive lymphoma. The principle ...
OUR PARTNERS
Copyright © 2022
Biosyngen Pte. Ltd.
Copyright © 2022 Biosyngen Pte. Ltd.
MENU
